About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Efficacy of Osimertinib in Patients With Lung Cancer

NCT06174857·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Yongchang C Zhang, MD
CONTACT
+8613873123436 zhangyongchang@csu.edu.cn
Nong Yang, MD
CONTACT
+8613055193557 yangnong0217@163.com

Lead

Hunan Province Tumor Hospital

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Patients must be ≥18 years.
Provision of fully informed consent prior to any study specific procedures.
Advanced or metastatic lung squamous cell carcinoma confirmed by histology or cytology.
According to the RECIST 1.1 standard, the patient must have at least one measurable lesion.

You may not be if

None

The record

StatusUnknown

PhaseNo phase

Taking part100

StartedJan 2021

UpdatedDec 18, 2023

Conditions

Advanced Non-Small Cell Lung Cancer

Where1

Hunan Cancer hospital
Changsha, Hunan, China

Clareo Health | Efficacy of Osimertinib in Patients With Lung Cancer